Ademi LLP Investigates Claims of Securities Fraud against Iovance Biotherapeutics, Inc.
MILWAUKEE, May 20, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA). The investigation results from inaccurate statements Iovance may have made regarding its financial results, business operations and prospects.
Click here to learn more about the investigation: https://www.ademilaw.com/case/iovance-biotherapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Iovance properly disclosed the facts underlying its submissions of potency assays for lifileucel to the FDA. On May 19, 2021, Iovance disclosed that its assay data package submitted in the first quarter was insufficient to fully satisfy FDA reviewers, and would require Iovance to submit additional assay data and meet with the FDA in the second half of 2021. Iovance's biologics license application submission for lifileucel is now expected to occur during the first half of 2022. Later that day, Iovance CEO Maria Fardis resigned.
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, https://www.ademilaw.com/case/iovance-biotherapeutics-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
View original content:http://www.prnewswire.com/news-releases/ademi-llp-investigates-claims-of-securities-fraud-against-iovance-biotherapeutics-inc-301296070.html
SOURCE Ademi LLP
